You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDapiprazole
Accession NumberDB00298  (APRD00902)
TypeSmall Molecule
GroupsApproved
DescriptionDapiprazole (U.S. trade name Rev-Eyes) is an alpha blocker. It is used to reverse mydriasis after eye examination. [Wikipedia]
Structure
Thumb
Synonyms
5,6,7,8-Tetrahydro-3-(2-(4-(O-tolyl)-1-piperazinyl)ethyl)-S-triazolo(4,3-a)pyridine
Dapiprazol
Dapiprazolum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Rev-EyesNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Dapiprazole hydrochloride
ThumbNot applicableDBSALT001438
Categories
UNII5RNZ8GJO7K
CAS number72822-12-9
WeightAverage: 325.4512
Monoisotopic: 325.226645889
Chemical FormulaC19H27N5
InChI KeyInChIKey=RFWZESUMWJKKRN-UHFFFAOYSA-N
InChI
InChI=1S/C19H27N5/c1-16-6-2-3-7-17(16)23-14-12-22(13-15-23)11-9-19-21-20-18-8-4-5-10-24(18)19/h2-3,6-7H,4-5,8-15H2,1H3
IUPAC Name
1-(2-methylphenyl)-4-(2-{5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyridin-3-yl}ethyl)piperazine
SMILES
CC1=CC=CC=C1N1CCN(CCC2=NN=C3CCCCN23)CC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentPhenylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Phenylpiperazine
  • Triazolopyridine
  • Aminotoluene
  • Substituted aniline
  • Dialkylarylamine
  • Aralkylamine
  • N-alkylpiperazine
  • Toluene
  • Aniline
  • Benzenoid
  • Pyridine
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • 1,2,4-triazole
  • Triazole
  • Azole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationUsed in the treatment of iatrogenically induced mydriasis produced by adrenergic (phenylephrine) or parasympatholytic (tropicamide) agents used in certain eye examinations.
PharmacodynamicsDapiprazole is an alpha-adrenergic blocking agent. It produces miosis by blocking the alpha-adrenergic receptors on the dilator muscle of the iris. Dapiprazole produces no significant action on ciliary muscle contraction and thus, there are no changes in the depth of the anterior chamber of the thickness of the lens. It does not alter the IOP either in normal eyes or in eyes with elevated IOP. The rate of pupillary constriction may be slightly slower in clients with brown irises than in clients with blue or green irises.
Mechanism of actionDapiprazole acts through blocking the alpha1-adrenergic receptors in smooth muscle. It produces miosis through an effect on the dilator muscle of the iris and does not have any significant activity on ciliary muscle contraction and, therefore does not induce a significant change in the anterior chamber depth or the thickness of the lens.
Related Articles
AbsorptionSystemic absorption is negligible.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityOral LD50 is 1189-2100 mg/kg in mice, rats and rabbits.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9832
Caco-2 permeable+0.5899
P-glycoprotein substrateSubstrate0.657
P-glycoprotein inhibitor IInhibitor0.8074
P-glycoprotein inhibitor IIInhibitor0.9107
Renal organic cation transporterInhibitor0.7481
CYP450 2C9 substrateNon-substrate0.8296
CYP450 2D6 substrateNon-substrate0.5563
CYP450 3A4 substrateSubstrate0.5833
CYP450 1A2 substrateInhibitor0.6905
CYP450 2C9 inhibitorNon-inhibitor0.5324
CYP450 2D6 inhibitorNon-inhibitor0.632
CYP450 2C19 inhibitorInhibitor0.7506
CYP450 3A4 inhibitorInhibitor0.7338
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9357
Ames testNon AMES toxic0.6215
CarcinogenicityNon-carcinogens0.8546
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7573 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6592
hERG inhibition (predictor II)Inhibitor0.7292
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Angelini pharmaceuticals inc
Packagers
  • American Cyanamid Co.
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySolubleNot Available
logP2.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.751 mg/mLALOGPS
logP2.78ALOGPS
logP2.42ChemAxon
logS-2.6ALOGPS
pKa (Strongest Basic)7.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area37.19 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity100.22 m3·mol-1ChemAxon
Polarizability38.23 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesS01EX02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (114 KB)
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineDapiprazole may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineDapiprazole may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with 7-Nitroindazole.
AcepromazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Dapiprazole is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Alfentanil.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Dapiprazole.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Alprazolam.
AmisulprideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Dapiprazole.
AmobarbitalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Amperozide.
AmphetamineDapiprazole may decrease the stimulatory activities of Amphetamine.
AripiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Aripiprazole.
ArticaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Asenapine.
AzaperoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Azaperone.
AzelastineDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Dapiprazole.
BaclofenThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Barbital.
BenzocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Benzocaine.
BenzphetamineDapiprazole may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Benzyl alcohol.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.
BrimonidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Bromazepam.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Dapiprazole.
BrompheniramineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dapiprazole.
BuprenorphineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Dapiprazole.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dapiprazole.
ButacaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Butorphanol.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Dapiprazole.
CarbamazepineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Carisoprodol.
CetirizineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chlordiazepoxide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chloroprocaine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chlorphenamine.
ChlorphentermineDapiprazole may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Cinchocaine.
CitalopramThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clorazepate.
ClozapineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clozapine.
CocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Codeine.
CyclizineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dapiprazole.
CyproheptadineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dantrolene.
DapoxetineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Dapiprazole.
DesloratadineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Dapiprazole.
DetomidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dexmedetomidine.
DextroamphetamineDapiprazole may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Dapiprazole.
DextromoramideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Diazepam.
DifenoxinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dihydrocodeine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Dapiprazole.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dihydromorphine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Diphenoxylate.
DoramectinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Dapiprazole.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.
DoxylamineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Dapiprazole is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.
DroperidolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Drotebanol.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Dapiprazole.
DyclonineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dyclonine.
EcgonineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Dapiprazole is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Dapiprazole.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Dapiprazole.
EntacaponeThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Entacapone.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Dapiprazole.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Dapiprazole.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Dapiprazole.
EscitalopramThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Eszopiclone.
EthanolDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Dapiprazole.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dapiprazole.
EthosuximideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Dapiprazole.
EtoperidoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Etorphine.
EzogabineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dapiprazole.
FexofenadineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Dapiprazole.
GabapentinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Dapiprazole is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Glutethimide.
GuanfacineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Halazepam.
HaloperidolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Hexobarbital.
HydrocodoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Hydrocodone.
HydromorphoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Hydromorphone.
Hydroxyamphetamine hydrobromideDapiprazole may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.
HydroxyzineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Dapiprazole.
IndalpineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Indalpine.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Dapiprazole.
IsofluraneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Isoflurane.
KetamineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ketobemidone.
LamotrigineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Levorphanol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dapiprazole.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Dapiprazole.
LisdexamfetamineDapiprazole may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Dapiprazole.
LithiumThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dapiprazole.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Dapiprazole.
LoxapineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Loxapine.
Lu AA21004The risk or severity of adverse effects can be increased when Dapiprazole is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Dapiprazole.
MeclizineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Melperone.
MephentermineDapiprazole may decrease the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Meprobamate.
MequitazineDapiprazole may increase the arrhythmogenic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Dapiprazole.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methadyl Acetate.
MethamphetamineDapiprazole may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methohexital.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methsuximide.
MethylphenidateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methylphenobarbital.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Dapiprazole.
MetyrosineDapiprazole may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Dapiprazole.
MidazolamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Midazolam.
MilnacipranThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.
MirtazapineDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Dapiprazole.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Dapiprazole.
MolindoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dapiprazole.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.
NabiloneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Nalbuphine.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Dapiprazole.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Dapiprazole.
NitrazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Dapiprazole.
OlanzapineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Opium.
OrphenadrineDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Dapiprazole.
OsanetantThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Oxybuprocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Oxymorphone.
PaliperidoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Paliperidone.
ParaldehydeDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Dapiprazole.
ParoxetineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pentobarbital.
PerampanelThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dapiprazole.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Dapiprazole.
PhenobarbitalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Phenoxyethanol.
PhentermineDapiprazole may decrease the stimulatory activities of Phentermine.
PhenytoinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pomalidomide.
PramipexoleDapiprazole may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dapiprazole.
PrilocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Prilocaine.
PrimidoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Procaine.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Dapiprazole.
ProchlorperazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Prochlorperazine.
PromazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Dapiprazole.
ProparacaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Proparacaine.
PropofolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dapiprazole.
PSD502The risk or severity of adverse effects can be increased when Dapiprazole is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Quetiapine.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Dapiprazole.
RamelteonThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ramelteon.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Dapiprazole.
RemifentanilThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dapiprazole.
RisperidoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Risperidone.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Dapiprazole.
RomifidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Romifidine.
RopiniroleDapiprazole may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dapiprazole.
RotigotineDapiprazole may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Dapiprazole.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Dapiprazole is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Secobarbital.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Dapiprazole.
SertindoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Sevoflurane.
Sodium oxybateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Sodium oxybate.
StiripentolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Sufentanil.
SulpirideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Dapiprazole.
SuvorexantThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Dapiprazole.
TasimelteonThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tasimelteon.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Dapiprazole.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Dapiprazole.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Dapiprazole.
TetracaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tetrodotoxin.
ThalidomideDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Dapiprazole.
ThiamylalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Thiopental.
ThioridazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tiagabine.
TiletamineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dapiprazole.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dapiprazole.
TrazodoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Triazolam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Triflupromazine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Dapiprazole.
TriprolidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Valproic Acid.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Dapiprazole.
VigabatrinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dapiprazole.
ZolazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Dapiprazole.
ZolpidemThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Zolpidem.
ZonisamideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Eltze M: Affinity of the miotic drug, dapiprazole, at alpha 1-adrenoceptor subtypes A, B and D. J Pharm Pharmacol. 1997 Nov;49(11):1091-5. [PubMed:9401944 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23